A drug, proven to improve walking in people with MS, has been approved and given standard marketing authorisation by the European Commission (EC).
Fampyra (prolonged release fampridine tablets) have gained approval based on the results of the phase III ENHANCE study. Which confirmed the clinical benefits and safety of the drug over the long term in people with both relapsing remitting and progressive MS.
Fampyra can be used alone or with existing MS therapies, including immunomodulatory drugs.
“Approximately 80 per cent of people with MS experience walking impairment, one of the most common issues with the disease. We frequently hear from people living with MS that these walking challenges affect their independence, restrict their ability to work and negatively impact their overall quality of life,” said Jeremy Hobart, Ph.D., Consultant Neurologist at Plymouth Hospitals NHS Trust and Professor of Clinical Neurology and Health Measurement at the Plymouth University Peninsula Schools of Medicine and Dentistry.
“Results from the ENHANCE study provided additional evidence that Fampyra is an effective treatment for MS and echoes what I and other clinicians have observed in treating people with MS - Fampyra provides a clinically significant improvement in walking ability, as well as on broader aspects of quality of life.”
Source: MS-UK (26/05/17)